Tests Alzheimer’s core blood/brain markers to set diagnostic cutoffs
Part of Brain & nervous system, Mental health clinical trials.
This study checks Alzheimer’s “core biomarkers” to find the best cut-off values for diagnosing Alzheimer’s disease and related conditions. It may help doctors more accurately tell Alzheimer’s, mild cognitive changes, and other causes of memory problems apart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between ages 55 and 75
- Have an Alzheimer’s or related diagnosis based on standard medical criteria (or be in a normal-cognition group)
- Be able to complete required memory/thinking tests (like MMSE/CDR)
- Provide a required sample for testing (a “biospecimen,” such as blood or other samples as requested)
- Have no other major medical or psychiatric illness that would interfere with the study
- Have someone who can help answer questions (“informant”)—or ensure the study allows what you can provide
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for specific markers (“seeds”) that may help doctors diagnose Alzheimer’s disease and distinguish it from other memory or thinking conditions. If you are in the right age range and can complete memory testing and provide a sample, you may help validate a diagnostic approach.
This study group collects detailed information from people with normal memory, mild cognitive impairment, or mild Alzheimer’s disease to support Alzheimer’s research. You may need multiple visits, brain scans, and sometimes a spinal fluid sample, with strict health and medication requirements to keep results clear.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
This study looks at people with probable Alzheimer's disease to see how certain blood biomarkers relate to their symptoms. It may help doctors better understand the disease and tailor care.
This study looks for “biomarkers” (measurable signs from blood and brain tests) that may help predict who with mild cognitive impairment (MCI) could later develop dementia. Results may help doctors spot risk earlier and better plan care.
This study aims to improve access to Alzheimer's disease diagnostics by using biomarkers (like blood tests or brain scans) to confirm whether your memory problems are caused by Alzheimer's disease. Participating could help you get a more accurate diagnosis and guide your care.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.